1. Home
  2. MCS vs DRUG Comparison

MCS vs DRUG Comparison

Compare MCS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marcus Corporation (The)

MCS

Marcus Corporation (The)

SELL

Current Price

$28.04

Market Cap

873.2M

ML Signal

SELL

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$51.94

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCS
DRUG
Founded
1935
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
873.2M
778.4M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
MCS
DRUG
Price
$28.04
$51.94
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$32.25
★ $152.40
AVG Volume (30 Days)
★ 188.4K
128.4K
Earning Date
10-29-2026
08-17-2026
Dividend Yield
★ 1.26%
N/A
EPS Growth
N/A
N/A
EPS
★ 0.77
N/A
Revenue
★ $758,458,000.00
N/A
Revenue This Year
$14.64
N/A
Revenue Next Year
$2.22
N/A
P/E Ratio
$37.21
★ N/A
Revenue Growth
★ 3.11
N/A
52 Week Low
$12.85
$47.23
52 Week High
$32.42
$123.75

Technical Indicators

Market Signals
Indicator
MCS
DRUG
Relative Strength Index (RSI) 54.73 41.28
Support Level $28.19 $47.23
Resistance Level $28.89 $55.78
Average True Range (ATR) 0.79 3.26
MACD 0.15 0.93
Stochastic Oscillator 62.17 58.25

Price Performance

Historical Comparison
MCS
DRUG

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: